June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
The long-term effect of intravitreal bevacizumab injection in central serous chorioretinopathy
Author Affiliations & Notes
  • In-Cheon You
    Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute, Jeonju, Republic of Korea
  • Namchon Cho
    Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute, Jeonju, Republic of Korea
  • Dongwook Lee
    Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute, Jeonju, Republic of Korea
  • Min Ahn
    Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute, Jeonju, Republic of Korea
  • Footnotes
    Commercial Relationships In-Cheon You, None; Namchon Cho, None; Dongwook Lee, None; Min Ahn, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2828. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      In-Cheon You, Namchon Cho, Dongwook Lee, Min Ahn; The long-term effect of intravitreal bevacizumab injection in central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2828. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To study the effect and safety of intravitreal bevacizumab injection in patients with idiopathic central serous chorioretinopathy.

Methods: We had performed retrospective review on the patients who had been diagnosed as idiopathic central serous chorioretinopathy and had regular follow-up for at least 12 months from the first injection at our hospital, either undergone intravitreal bevacizumab injection (107 eyes of 100 patients) or observed without injection (46 eyes of 40 patients). Changes in the visual acuity and the serous neurosensory and retinal pigment epithelium retinal detachment were evaluated through the results of best corrected visual acuity and optical coherence tomography measured respectively at initial presentation, after 1month, 3months, 6months, 9months and 12months of the first injection.

Results: 87 males and 13 females with mean age of 45.43±7.6 years were recruited in the intravitreal bevacizumab injection group, and 34 males and 6 females with mean age of 47.22±9.8 years were recruited in the observation group. There was significant difference in the mean duration of retinal detachment to disappear between the intravitreal bevacizumab injection group and the observation group (2.54±0.21 : 4.29±0.73 months, p<0.01). Resolution rate (87.9% : 76.1%. p=0.27)and recurrence rate (22.4% : 32.6%, p=0.21) do not show significant difference between the two groups. There were no significant differences in the best corrected visual acuity and the central macular thickness after 12 months follow-up between the intravitreal bevacizumab injection group and the observation group.

Conclusions: Intravitreal bevacizumab injection was more effective and faster resolution of sensory retinal detachment than observation during the 12 months of consecutive follow-up. Therefore, intravitreal bevacizumab injection can be considered as a effective and safe treatment modality when the patients need prompt visual improvement, such as depending on the morbid eye or requiring binocular vision for occupational cause.

Keywords: 748 vascular endothelial growth factor • 451 chorioretinitis  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×